ArticleInternational journal of molecular sciences2022
Potent CCR3 Receptor Antagonist, SB328437, Suppresses Colonic Eosinophil Chemotaxis and Inflammation in the
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Investigating the Effects of a CCR3 Antagonist and SP-A Eosinophil Suppressor Tetrapeptide-Transduced Mesenchymal Stem Cells in Allergic Asthma.Applied biochemistry and biotechnology · 2026Article
- Rediscovering eosinophil identity through tissue adaptation.Nature immunology · 2026Review
- Type 2 immune history imprints local training in nerve and airway associated interstitial macrophages (NAMs) for disease tolerance during lethal respiratory viral infection.Research square · 2026Article
- Macrophage-Derived CCL24 Promotes Cardiac Fibrosis Via Fibroblast CCR3.Circulation research · 2025Article
- Winnie Mice: A Chronic and Progressive Model of Ulcerative Colitis.Inflammatory bowel diseases · 2025Review
- Padua Days on Muscle and Mobility Medicine, March 25-29, 2025, Hotel Petrarca, Euganean Thermae, Italy: Program and Abstracts.European journal of translational myology · 2025Article
- Age-related alterations in gut homeostasis are microbiota dependent.NPJ biofilms and microbiomes · 2025Article
- Inflammatory and homeostatic roles of eosinophil subpopulations in chronic rhinosinusitis with nasal polyp pathogenesis.Frontiers in immunology · 2025Review
- An in silico framework to visualize how cancer-associated mutations influence structural plasticity of the chemokine receptor CCR3.Protein science : a publication of the Protein Society · 2025Article
- Eosinophils in inflammatory bowel disease pathogenesis: an ROS-centric view.Frontiers in allergy · 2025Article
- Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease.Nature reviews. Immunology · 2024Review
- Targeting CCR3 with antagonist SB 328437 sensitizes 5‑fluorouracil‑resistant gastric cancer cells: Experimental evidence and computational insights.Oncology letters · 2024Article
- Alterations in tryptophan metabolism andFrontiers in medicine · 2024Article
- Review
- Oxidative Stress-Induced HMGB1 Translocation in Myenteric Neurons Contributes to Neuropathy in Colitis.Biomolecules · 2022Article
- Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease.Frontiers in immunology · 2022Review
- Construction and validation of a prediction model for cystitis glandularis using serological markers combined with histological indexes to predict recurrence risk.Therapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Eosinophils and their regulatory molecules have been associated with chronic intestinal inflammation and gastrointestinal dysfunctions; eosinophil accumulation in the gut is prominent in inflammatory bowel disease (IBD). The chemokine receptor CCR3 plays a pivotal role in local and systemic recruitment and activation of eosinophils. In this study, we targeted CCR3-ligand interactions with a potent CCR3 receptor antagonist, SB328437, to alleviate eosinophil-associated immunological responses in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.